Used as an intermediate in the synthesis of pharmaceutical compounds, particularly in the development of kinase inhibitors for cancer treatment. The structure features a 4-bromo-3-methylisoxazol-5-yl group attached to a cyclopropyl carbamate protected by a tert-butyl (Boc) group. The bromo and methyl substituents on the isoxazole enhance binding affinity to biological targets, while the cyclopropane ring introduces strain for improved specificity and stability in biological systems. The Boc group serves as a nitrogen protecting group, enabling controlled reactivity during synthesis of complex derivatives. This allows for selective modification, making it valuable in constructing biologically active molecules. Commonly employed in medicinal chemistry as a building block in drug discovery due to the stability and reactivity of the isoxazole and carbamate groups. Also utilized in agrochemical research for designing novel active ingredients with improved metabolic stability. It is typically used in intermediate steps of new drug development processes.